Proactive Investors - Run By Investors For Investors

Motif Bio to present positive iclaprim drug data in the US this week

The biopharma firm said trials confirmed that iclaprim is non-inferior to vancomycin and significantly safer
Motif Bio to present positive iclaprim drug data in the US this week
Iclaprim could be a valuable treatment option for patients with wound infections

Motif Bio PLC (LON:MTFB) plans to present data showing the safety and efficacy of its next-generation antibiotic iclaprim compared to the current gold standard medication, vancomycin.

The company said on Wednesday that it plans to present its data and the results of the REVIVE Phase 3 trials at IDWeek being held in San Francisco later this week.

READ: Pooled data from phase III trials confirms Motif Bio’s iclaprim drug is safer than gold standard

Motif Bio said 50% (602 out of 1198) of the REVIVE intent-to-treat (ITT) population had wound infections and that iclaprim was just as effective as vancomycin, based on an early clinical response of a subgroup of patients with wound infections. 

The company also repeated that its drug was found not to negatively affect patients’ kidney function, a key issue for some people taking rival treatments. None of the patients taking iclaprim showed signs of kidney toxicity, compared to two patients in the vancomycin arm.

"Wound infections, including surgical site infections, can be difficult to treat and it was important to see that iclaprim was non-inferior to standard of care in treating these types of infections,” G. Ralph Corey, MD, Vice Chair for Education and Global Health and Gary Hock Professor at Duke University School of Medicine and a principal investigator in the REVIVE-2 trial, said in a statement.

“Iclaprim, if approved, could be a valuable treatment option for patients with wound infections … including patients with co-morbidities known to increase the risk of vancomycin-associated acute kidney injury, such as renal impairment, diabetes and obesity," he added.

Shares in Motif Bio were flat at 34.95p in early trade.

View full MTFB profile View Profile

Motif Bio PLC Timeline

May 07 2019

Related Articles

lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use